To deliver PD1/PDL1 checkpoint Ab for patients with GBM, we engineered our EGFRvIII-targeted CAR T cells to function as bio-factories, producing and secreting anti-PD1 mini-Abs in situ at the site of GBM. Here, PDCD1 is linked to glioblastoma.